N/A
N=33
Therapeutic Magnetic Resonance Imaging (MRI)-Guided High Intensity Focused Ultrasound (HIFU) Ablation of Uterine Fibroids
Uterine Fibroids
Bottom Line
View on ClinicalTrials.gov: NCT00897897 ↗Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Nov 2011
Primary outcome: Primary: Adverse Events/Subject Resulting From HIFU Treatment of the Uterine Fibroids — 2.6 Adverse Event/subject
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Philips MRI-guided HIFU system (Device)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Philips Healthcare
- Primary completion
- Dec 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Adverse Events/Subject Resulting From HIFU Treatment of the Uterine Fibroids |
2.6 | — |
| SECONDARY Fibroid Symptom Severity Score (SSS) From the Uterine Fibroid Symptoms - Quality of Life (UFS-QoL) Questionnaire. |
-13.6 | — |
Summary
This study is to confirm the safety and technical effectiveness of MRI guided High Intensity Focused Ultrasound (HIFU) in ablating uterine tissue associated with symptomatic leiomyomas. The importance of this therapy is that it offers a non-invasive, uterine sparing procedure for the treatment of uterine fibroids in pre- and peri- menopausal women.
MRI guided high intensity focused ultrasound uses ultrasound to heat and thermally ablate fibroid tissue. The MRI system identifies the ultrasound path and monitors heat rise in the fibroid tissue. The goal of the study is to show treatment safety and technical effectiveness. MR-guided HIFU will be performed in patients who pass inclusion/exclusion criteria. Safety, quality of life, and imaging endpoints will be evaluated in all study patients.
The goal of this study is to demonstrate that:
1. The safety profile is acceptable (safety)
2. Actual MR-HIFU ablated volumes (as measured with contrast enhanced MRI) match the intended volumes (technical effectiveness)
3. When intended, volumes greater than 20% of the fibroid volume can be successfully ablated (technical effectiveness)
The investigators' hypothesis is that greater than 70% of fibroids will have concordance between intended lesion volume and actual lesion volume while maintaining an acceptable safety profile.
Eligibility Criteria
Inclusion Criteria
- Women, age between 18 and 59 years
- Weight 40
- Normal Cervical cell assessment by PAP
- Symptomatic Fibroid disease
- Dominant fibroid greater than or equal to 3cm and less than or equal to 12 cm
Exclusion Criteria
- Other Pelvic Disease
- Desire for future pregnancy
- Significant systemic disease even if controlled
- Positive pregnancy test
- Hematocrit < 25%
- Scarring or other interference of the HIFU beam
- MRI or contrast contraindicated
- Fibroids not quantifiable on MRI
- Calcifications around or throughout uterine tissues
- Communication barrier
Data sourced from ClinicalTrials.gov (NCT00897897). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.